Recent Posts

Hypothyroxinemia and TPO-Antibody Positivity Are Risk Factors for Premature Delivery

Hypothyroxinemia and TPO-Antibody Positivity Are Risk Factors for Premature Delivery: The Generation R Study. Korevaar TI, Schalekamp-Timmermans S, de Rijke YB, Visser WE, Visser W, de Muinck Keizer-Schrama SM, Hofman A, Ross HA, Hooijkaas H, Tiemeier H, Bongers-Schokking JJ, Jaddoe VW, Visser TJ, Steegers EA, Medici M, Peeters RP. J Clin Endocrinol Metab. 2013 Nov;98(11):4382-90. […]

Read more »

Birth defects after early pregnancy use of antithyroid drugs:

Birth defects after early pregnancy use of antithyroid drugs: a danish nationwide study. Andersen SL, Olsen J, Wu CS, Laurberg P. J Clin Endocrinol Metab. 2013 Nov;98(11):4373-81. doi: 10.1210/jc.2013-283 Hyperthyroidism in pregnant women should be adequately treated to prevent maternal and fetal complications, but teratogenic effects of antithyroid drug (ATD) treatment have been described. Evidence […]

Read more »

Does BRAF V600E mutation predict aggressive features in papillary thyroid cancer? Results from four endocrine surgery centers

.Li C, Aragon Han P, Lee KC, Lee LC, Fox AC, Beninato T, Thiess M, Dy BM, Sebo TJ, Thompson GB, Grant CS, Giordano TJ, Gauger PG, Doherty GM, Fahey TJ 3rd, Bishop J, Eshleman JR, Umbricht CB, Schneider EB, Zeiger MA. J Clin Endocrinol Metab. 2013 Sep;98(9):3702-12. Existing evidence is controversial regarding the association between BRAF mutation status and aggressive features of papillary thyroid cancer (PTC). Specifically, no study has incorporated multiple surgical practices […]

Read more »

The clinical consequences of variation in thyroid function within the reference range.

Taylor PN, Razvi S, Pearce SH, Dayan CM. J Clin Endocrinol Metab. 2013 Sep;98(9):3562-71. Overt thyroid disease is associated with profound adverse health outcomes; however, data are conflicting for studies of borderline/subclinical thyroid dysfunction. Many studies of subclinical thyroid disease have had low power and were prone to selection bias. In contrast, large datasets are available from community studies […]

Read more »

Nonsurgical, image-guided, minimally invasive therapy for thyroid nodules

Gharib H, Hegedüs L, Pacella CM, Baek JH, Papini E. J Clin Endocrinol Metab. 2013 Oct;98(10):3949-57. Nodular thyroid disease is very common. Most nodules are asymptomatic, are benign by fine-needle aspiration, remain stable, and can be followed by observation alone in the majority of the patients. Occasionally, nodules grow or cause symptoms requiring treatment. So far, surgery has been our […]

Read more »

Recent Posts

Hypothyroxinemia and TPO-Antibody Positivity Are Risk Factors for Premature Delivery

Hypothyroxinemia and TPO-Antibody Positivity Are Risk Factors for Premature Delivery: The Generation R Study. Korevaar TI, Schalekamp-Timmermans S, de Rijke YB, Visser WE, Visser W, de Muinck Keizer-Schrama SM, Hofman A, Ross HA, Hooijkaas H, Tiemeier H, Bongers-Schokking JJ, Jaddoe VW, Visser TJ, Steegers EA, Medici M, Peeters RP. J Clin Endocrinol Metab. 2013 Nov;98(11):4382-90. […]

Read more »

Birth defects after early pregnancy use of antithyroid drugs:

Birth defects after early pregnancy use of antithyroid drugs: a danish nationwide study. Andersen SL, Olsen J, Wu CS, Laurberg P. J Clin Endocrinol Metab. 2013 Nov;98(11):4373-81. doi: 10.1210/jc.2013-283 Hyperthyroidism in pregnant women should be adequately treated to prevent maternal and fetal complications, but teratogenic effects of antithyroid drug (ATD) treatment have been described. Evidence […]

Read more »

Does BRAF V600E mutation predict aggressive features in papillary thyroid cancer? Results from four endocrine surgery centers

.Li C, Aragon Han P, Lee KC, Lee LC, Fox AC, Beninato T, Thiess M, Dy BM, Sebo TJ, Thompson GB, Grant CS, Giordano TJ, Gauger PG, Doherty GM, Fahey TJ 3rd, Bishop J, Eshleman JR, Umbricht CB, Schneider EB, Zeiger MA. J Clin Endocrinol Metab. 2013 Sep;98(9):3702-12. Existing evidence is controversial regarding the association between BRAF mutation status and aggressive features of papillary thyroid cancer (PTC). Specifically, no study has incorporated multiple surgical practices […]

Read more »

The clinical consequences of variation in thyroid function within the reference range.

Taylor PN, Razvi S, Pearce SH, Dayan CM. J Clin Endocrinol Metab. 2013 Sep;98(9):3562-71. Overt thyroid disease is associated with profound adverse health outcomes; however, data are conflicting for studies of borderline/subclinical thyroid dysfunction. Many studies of subclinical thyroid disease have had low power and were prone to selection bias. In contrast, large datasets are available from community studies […]

Read more »

Nonsurgical, image-guided, minimally invasive therapy for thyroid nodules

Gharib H, Hegedüs L, Pacella CM, Baek JH, Papini E. J Clin Endocrinol Metab. 2013 Oct;98(10):3949-57. Nodular thyroid disease is very common. Most nodules are asymptomatic, are benign by fine-needle aspiration, remain stable, and can be followed by observation alone in the majority of the patients. Occasionally, nodules grow or cause symptoms requiring treatment. So far, surgery has been our […]

Read more »